Anika Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-10.9M | $-56.4M | $-82.7M | $-14.9M | $4.1M | $-24.0M | $27.2M | $18.7M |
| Depreciation & Amortization | $5.4M | $6.9M | $6.4M | $6.7M | $6.5M | $6.1M | $5.0M | $5.9M |
| Depreciation | $5.4M | $5.0M | $4.9M | $4.9M | $6.5M | $6.1M | $5.0M | $4.9M |
| Amortization | $400.0K | $700.0K | $600.0K | $600.0K | $7.8M | $7.4M | $1.0M | $1.0M |
| Stock-Based Compensation | $10.1M | $13.1M | $15.2M | $14.3M | $11.1M | $5.4M | $6.1M | $11.0M |
| Net Cash from Operating Activities | $11.2M | $5.4M | $-1.8M | $4.4M | $8.4M | $13.1M | $37.0M | $34.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $6.8M | $7.7M | $5.4M | $7.5M | $5.1M | $1.6M | $2.8M | $4.7M |
| Business Acquisitions | — | — | $0 | $0 | $476.0K | $94.6M | $0 | $0 |
| Net Cash from Investing Activities | $-401.0K | $-8.3M | $-5.4M | $-7.5M | $-3.1M | $-71.3M | $39.7M | $-50.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $9.5M | $10.9M | $5.0M | $0 | $0 | $0 | $30.0M | $30.0M |
| Net Cash from Financing Activities | $-10.6M | $-12.7M | $-6.3M | $-4.9M | $-6.8M | $-3.8M | $-8.1M | $-28.9M |
| Net Change in Cash | $322.0K | $-15.7M | $-13.5M | $-8.1M | $-1.4M | $-61.6M | $68.4M | $-44.2M |
| Free Cash Flow | $4.4M | $-2.3M | $-7.2M | $-3.1M | $3.3M | $11.4M | $34.2M | $30.3M |